NCT02853305View on ClinicalTrials.gov

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,010

Participants

Timeline

Start Date

September 15, 2016

Primary Completion Date

April 29, 2020

Study Completion Date

September 15, 2022

Conditions

Urothelial Carcinoma Associated 1 RNA, Human

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Gemcitabine

IV infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02853305 - Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) | Biotech Hunter | Biotech Hunter